Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Immunotherapy entities : Bristol-myers squibb company save search
Global Cancer Immunotherapy Market Poised to Exceed US$ 188 Billion by 2030, with CAGR of 10.02%
Published: 2023-12-14 (Crawled : 01:00) - prnewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -1.67%
H: 1.17%
C: 0.85%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 1.81%
H: 0.0%
C: 0.0%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 1.16%
H: 0.14%
C: -1.89%
AMGN | $266.895 1.58% 950K
|
Health Technology
|
| O: -0.11%
H: 0.5%
C: -1.78%
cancer global immunotherapy market
Locally Advanced Pancreatic Cancer Market Report 2023-2028: Recent Advancements in Immunotherapy Inject New Hope into LAPC Market
Published: 2023-11-21 (Crawled : 23:00) - prnewswire.com
AZNCF | $138.24 800
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: -0.05%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.56%
H: 1.53%
C: 1.37%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -0.89%
H: 0.33%
C: -0.16%
report hope cancer pancreatic immunotherapy market
Global Immunotherapy Drugs Market Report to 2028 - Players Include F. Hoffmann-La Roche, GSK, Merck & Co, Pfizer and Sanofi
Published: 2023-02-11 (Crawled : 16:20) - prnewswire.com
AZN | $68.3 -0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.24 800
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.89 1.22% 5.1M
|
Health Technology
| Email alert
Add to watchlist
global immunotherapy report sanofi market
Intensity Therapeutics' INT230-6 Data will be presented at the 2022 Society for Immunotherapy of Cancer Meeting
Published: 2022-11-11 (Crawled : 13:00) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -1.61%
H: 0.45%
C: -2.74%
int230 immunotherapy meeting cancer
Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
AZNCF | $138.24 800
|
Health Technology
|
| O: 6.22%
H: 3.13%
C: -0.56%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: 2.59%
H: 0.72%
C: 0.63%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
IOVA M | $11.3 -3.58% 2.8M
|
Health Technology
|
| O: 6.12%
H: 4.99%
C: 4.21%
INO 3 d | $9.7 -4.9% 230K
|
Health Technology
|
| O: 5.5%
H: 4.35%
C: 3.48%
GILD | News | $66.33 0.26% 2.8M
|
Health Technology
|
| O: 1.43%
H: 0.36%
C: -1.08%
ATRA | $0.6782 -1.95% 880K
|
Health Technology
|
| O: 2.58%
H: 23.12%
C: 20.85%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 7.08%
H: 0.84%
C: -0.43%
ADAP | $1.005 11.87% 1.2M
|
Health Technology
|
| O: 0.0%
H: 7.14%
C: 5.71%
covid-19 research global immunotherapy report impact technology market
Cancer Immunotherapy Market Expands with Rising Adoption of Target Therapy in Cancer Treatment, States TMR Report
Published: 2022-06-27 (Crawled : 16:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.47%
H: 3.73%
C: 3.73%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
AZNCF | $138.24 800
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: -0.16%
H: 0.61%
C: 0.18%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.34%
H: 1.72%
C: 0.95%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.0%
H: 2.28%
C: -2.27%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
immunotherapy report therapy cancer market treatment
Global Cancer Immunotherapy Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Published: 2022-04-06 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
AZNCF | $138.24 800
|
Health Technology
|
| O: 1.45%
H: 0.46%
C: 0.19%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -1.11%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.39%
H: 0.53%
C: 0.44%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.27%
H: 2.95%
C: 1.12%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.05%
H: 2.52%
C: 2.49%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.35%
H: 2.64%
C: 2.45%
AMGN | $266.895 1.58% 950K
|
Health Technology
|
| O: -0.29%
H: 1.42%
C: 0.98%
immunotherapy cancer market
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
Published: 2022-03-30 (Crawled : 12:20) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.59%
H: 0.75%
C: 0.27%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
REPL | $6.56 -5.88% 310K
|
Health Technology
|
| O: 0.72%
H: 4.53%
C: 1.25%
program immunotherapy
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb
Published: 2022-03-01 (Crawled : 19:00) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -0.8%
H: 1.31%
C: 0.75%
il-12 program therapeutics immunotherapy one phase 1 therapy phase 2 milestone
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Published: 2021-11-13 (Crawled : 16:20) - prnewswire.com
BMY | $48.89 1.22% 5.1M
|
Health Technology
| Email alert
Add to watchlist
INTS | $3.82 0.26% 940
|
| Email alert
Add to watchlist
immunotherapy solid tumors therapy results cancer
Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
GRTS | $0.7241 -2.64% 1.1M
|
Health Technology
|
| O: 3.4%
H: 0.0%
C: 0.0%
immunotherapy positive therapy cancer colorectal cancer trial program
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
Published: 2021-09-17 (Crawled : 12:00) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
GRTS | $0.7241 -2.64% 1.1M
|
Health Technology
|
| O: 3.4%
H: 0.0%
C: 0.0%
phase 2 immunotherapy therapy trial solid tumors
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
Published: 2021-09-13 (Crawled : 14:00) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.54%
H: 0.06%
C: -0.99%
treatment immunotherapy potential positive therapy cancer
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Metastatic Urothelial Cancer
Published: 2021-09-09 (Crawled : 13:15) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -0.74%
H: 0.49%
C: -1.33%
immunotherapy therapy collaboration cancer trial nivolumab
Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
Published: 2021-09-08 (Crawled : 12:00) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -0.89%
H: 0.82%
C: 0.48%
cancer research immunotherapy
Global Leukemia Therapeutics Markets, 2016-2020 & 2021-2026 - Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, & Others
Published: 2021-04-21 (Crawled : 17:00) - prnewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.56%
H: 0.72%
C: 0.38%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.5%
H: 0.76%
C: -0.32%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.3%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.7%
H: 1.5%
C: 0.92%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 1.24%
H: 0.48%
C: 0.36%
AMGN | $266.895 1.58% 950K
|
Health Technology
|
| O: 0.49%
H: 0.23%
C: -0.63%
immunotherapy stem cell therapy leukemia
FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer
Published: 2021-04-16 (Crawled : 17:00) - fda.gov
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: 0.76%
H: 1.09%
C: 0.82%
cancer treatment fda approval fda approval immunotherapy
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
AULT | $0.2998 23.83% 53M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.